Literature DB >> 19327101

Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation.

M H Kim1, J Lin, M Hussein, D Battleman.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is prevalent and has a high cost burden. Among the main drivers of cost is inpatient care; however, little is known about patterns of hospital readmissions for AF.
OBJECTIVE: To evaluate the incidence and temporal pattern of readmission in AF patients.
METHODS: This retrospective, cohort analysis used claims data from the Integrated Healthcare Information Systems National Managed Care Benchmark Database for 2002-2006. Patients hospitalized for AF (primary discharge diagnosis) were identified. Data on the first readmission for AF over 1 year following an index hospitalization were analyzed for chronic AF (any AF-related claims in 1 year before index hospitalization) and newly-diagnosed AF patients (no prior AF-related claims).
RESULTS: Overall, 4174 patients hospitalized with primary AF were identified; 1637 had chronic AF and 2537 newly-diagnosed AF. Mean age of chronic AF patients was 62.4 years and 61.2% were male; for newly-diagnosed AF, mean age was 61.4 years and 57.8% were male. In the year following index hospitalization, 12.5% of chronic AF patients were readmitted for AF, with a mean time to readmission of 142.5 days (median 108 days). Among newly-diagnosed AF patients, 10.1% were readmitted for AF, with a mean time to readmission of 133.8 days (median 112 days). For chronic AF, 17.6%, 43.4%, and 65.8% of readmissions occurred within 1, 3, and 6 months, respectively, versus 22.7%, 44.5%, and 67.2%, respectively, for newly-diagnosed AF. LIMITATIONS: Limited data were available on patients' clinical profile, treatment patterns, or the reasons for hospitalization/readmission. The term chronic AF only captured patients with a history of AF and data were not available to classify patients according to the presence of paroxysmal, permanent, or persistent AF.
CONCLUSIONS: Patients with newly-diagnosed or chronic AF are often readmitted in the year following hospitalization with most readmissions occurring within 6 months of the index hospitalization.

Entities:  

Mesh:

Year:  2009        PMID: 19327101     DOI: 10.1185/03007990902869235

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  7 in total

1.  Leveraging Real-World Evidence in Disease-Management Decision-Making with a Total Cost of Care Estimator.

Authors:  Thanh-Nghia Nguyen; Jeffrey Trocio; Stacey Kowal; Cheryl P Ferrufino; Julie Munakata; Dell South
Journal:  Am Health Drug Benefits       Date:  2016-12

2.  Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States.

Authors:  Gerald V Naccarelli; Stephen S Johnston; Jay Lin; Parag P Patel; Kathy L Schulman
Journal:  Clin Cardiol       Date:  2010-05       Impact factor: 2.882

3.  Costs and clinical consequences of suboptimal atrial fibrillation management.

Authors:  Steven N Singh
Journal:  Clinicoecon Outcomes Res       Date:  2012-03-26

4.  A systematic review protocol for examining 30-day readmission costs for atrial fibrillation patients.

Authors:  Taylor-Jade Woods; Peter Speck; Billingsley Kaambwa
Journal:  BMJ Open       Date:  2019-10-10       Impact factor: 2.692

5.  A multidisciplinary atrial fibrillation clinic.

Authors:  Huyentran N Tran; Javad Tafreshi; Elvin A Hernandez; Sudha M Pai; Vilma I Torres; Ramdas G Pai
Journal:  Curr Cardiol Rev       Date:  2013-02-01

Review 6.  Cost-Effectiveness of Cardiac Radiosurgery for Atrial Fibrillation: Implications for Reducing Health Care Morbidity, Utilization, and Costs.

Authors:  Nikhilesh Bhatt; Mintu Turakhia; Thomas J Fogarty
Journal:  Cureus       Date:  2016-08-01

Review 7.  Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2018-10-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.